VIZ Plain Royal Blue Adjustable Baseball Cap

Product Information

The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty ® or Moderna Spikevax ®) should be offered for your second dose. Find detailed technical information such as the product monograph and the regulatory decision summary: The Moderna Spikevax®Monovalent COVID-19 vaccine(Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. It may be given to people who have been previously vaccinated or who have not been previously vaccinated. After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination. The monovalent Omicron XBB 1.5 subvariant multi-dose vial has a royal blue plastic cap and coral blue label.

months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen. Dose volume depends on which series of the vaccine is being administered. The dose for people 12 years of age and older (100 micrograms) is: Primary series in individuals age 6 months and older, or as a booster dose in individuals age 12 years and older: Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report. Vaccine review, approval and monitoring The safety and effectiveness of the Moderna Spikevax® Monovalent COVID-19 vaccine (Omicron XBB 1.5) is based on studies of Spikevax® (Original, Original/Omicron BA.1 & XBB.1.5). Dosage Primary series

Racing

Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence. The safety and effectiveness of the Moderna Spikevax ® Bivalent COVID-19 vaccine(Original/Omicron BA. 4/5) is based on studies of Spikevax ® Bivalent (Original/Omicron BA.1).

A severe allergic (anaphylaxis) reaction is also rare. Signs and symptoms of anaphylaxis may include:to 11 years (25 micrograms at least 6 months after their previous dose) Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1), Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) Omicron XBB.1.5 subvariant vaccine doses The Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) was shown to increase the immune response against the Omicron BA.1 variant. This means that the booster is expected to offer protection against this variant. years and older (50 micrograms at least 4 months after their previous dose) Moderna Spikevax ®COVID-19 vaccine, Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1), Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) The mRNA sequence from Moderna Spikevax ® COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.1 variant. Its safety and effectiveness in people younger than 6 months has not yet been established. Effectiveness

The mRNA sequence from Moderna Spikevax ®COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.4/5 variants. Other ingredients Moderna Spikevax ® Monovalent Omicron COVID-19 vaccine (Omicron XBB.1.5 subvariant) regulatory information As COVID-19 vaccines are administered across Canada, our safety monitoring is ongoing. The Public Health Agency of Canada, Health Canada, and provincial and territorial health authorities continue to:Call emergency services if you develop or witness any serious symptoms that could be anallergic reactionafter vaccination. Reporting a possible serious reaction